Shaping the Future of Retinal Vascular Disease Treatment

home / state-of-sciences-presentations / shaping-the-future-of-retinal-vascular-disease-treatment

Experts discuss the latest treatments for neovascular AMD, DME, and RVO, highlighting key efficacy and safety trial data along with case examples.

4 KOLs are featured in this series.

EP. 1: Overview of Real-World Outcomes for nAMD, DME, and RVO Patients

Carl D. Regillo, MD, FACS;Margaret A Chang, MD, MS ;Dante J. Pieramici, MD;John W. Kitchens, MD
October 16th 2024

Carl D Regillo, MD, FACS, begins the discussion highlighting each disease state and the landscape of treatment.

4 KOLs are featured in this series.

EP. 2: Faricimab for nAMD: Key Trial Highlights and Case Example

Carl D. Regillo, MD, FACS;Margaret A Chang, MD, MS ;Dante J. Pieramici, MD;John W. Kitchens, MD
October 16th 2024

Margaret A Chang, MD, MS, discusses efficacy and safety results of faricimab for neovascular age-related macular degeneration (nAMD) treatments.

4 KOLs are featured in this series.

EP. 3: Faricimab for DME: Durability and Patient Outcomes

Carl D. Regillo, MD, FACS;Margaret A Chang, MD, MS ;Dante J. Pieramici, MD;John W. Kitchens, MD
October 16th 2024

Dante J Pieramici, MD, shifts the conversation to diabetic macular edema (DME) and the promising drying and anatomical results from an open-label long-term extension trial.

4 KOLs are featured in this series.

EP. 4: Anti-VEGF for RVO: The Gold Standard

Carl D. Regillo, MD, FACS;Margaret A Chang, MD, MS ;Dante J. Pieramici, MD;John W. Kitchens, MD
October 16th 2024

John W Kitchens, MD, bookends the discussion by highlighting the landscape of branch vein occlusion (BRVO) treatment options.

© 2024 MJH Life Sciences

All rights reserved.